Enfusion, Inc. (NYSE:ENFN) General Counsel Sells $12,409.88 in Stock

Enfusion, Inc. (NYSE:ENFNGet Free Report) General Counsel Matthew Campobasso sold 1,081 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $12,409.88. Following the sale, the general counsel now owns 72,641 shares in the company, valued at approximately $833,918.68. The trade was a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Matthew Campobasso also recently made the following trade(s):

  • On Tuesday, January 7th, Matthew Campobasso sold 976 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total value of $9,886.88.

Enfusion Trading Down 1.4 %

Shares of ENFN stock opened at $11.29 on Friday. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of 282.20, a PEG ratio of 1.85 and a beta of 0.95. The firm has a 50-day moving average price of $10.96 and a 200 day moving average price of $9.86. Enfusion, Inc. has a twelve month low of $7.83 and a twelve month high of $11.80.

Enfusion (NYSE:ENFNGet Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The firm had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. As a group, research analysts predict that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Institutional Investors Weigh In On Enfusion

Several hedge funds have recently made changes to their positions in ENFN. KLP Kapitalforvaltning AS purchased a new position in Enfusion during the fourth quarter worth about $75,000. Harbor Capital Advisors Inc. increased its stake in shares of Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after acquiring an additional 1,315 shares during the last quarter. Belvedere Trading LLC purchased a new position in shares of Enfusion during the 3rd quarter worth about $114,000. Millennium Management LLC purchased a new position in shares of Enfusion during the 4th quarter worth about $114,000. Finally, Dark Forest Capital Management LP acquired a new stake in shares of Enfusion in the fourth quarter worth approximately $128,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

Wall Street Analysts Forecast Growth

ENFN has been the topic of a number of research reports. Piper Sandler increased their price objective on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Finally, Stifel Nicolaus raised their price objective on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $11.13.

Get Our Latest Stock Report on Enfusion

Enfusion Company Profile

(Get Free Report)

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.

Recommended Stories

Insider Buying and Selling by Quarter for Enfusion (NYSE:ENFN)

Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.